ASTRAZENECA SELECTS LOCATION FOR NEW GLOBAL R&D CENTRE AND CORPORATE HEADQUARTERS IN CAMBRIDGE, UK

Move brings AstraZeneca’s small molecule and MedImmune’s biologics research and
development together at purpose-built facility on Cambridge Biomedical Campus
18 June 2013

AstraZeneca today announced that its new UK-based global research and
development centre and corporate headquarters will be located at the Cambridge
Biomedical Campus on the southern outskirts of the city. By 2016, the new site
will house a highly-skilled workforce of approximately 2,000.

As announced on 18 March 2013 (http://www.astrazeneca.com/Media/Press
-releases/Article/18032013--astrazeneca-to-invest-research-centre-and-global
-hq), the investment in a £330 million facility in Cambridge is part of the
company’s move to create strategic global R&D centres in the UK, US and Sweden
to improve pipeline productivity and to establish AstraZeneca as a global leader
in biopharmaceutical innovation.

The purpose-built site in Cambridge will bring together AstraZeneca’s small
molecule and biologics research and development activity, opening up
opportunities to exploit the promise of small and large molecule combinations.
The Cambridge Biomedical Campus will be the new UK home for biologics research
and protein engineering carried out by MedImmune, AstraZeneca’s biologics arm.
MedImmune already employs around 500 people at Granta Park, to the south east of
the city.

The new site will also become the company’s largest centre for oncology research
as well as hosting scientists focused on cardiovascular and metabolic diseases,
respiratory, inflammation and autoimmune diseases and conditions of the central
nervous system. Work carried out in Cambridge will include medicinal chemistry
and high-throughput screening and the facility will accommodate a number of
AstraZeneca’s pre-clinical research capabilities. Other global functions will
join the research and development teams at the new facility and Cambridge will
become AstraZeneca’s corporate headquarters.

The Cambridge Biomedical Campus site is a growing and thriving hub for world
-renowned biomedical activity. It is home to leading research, academic and
healthcare organisations including the University of Cambridge School of
Clinical Medicine, Addenbrooke’s Hospital, the Medical Research Council (MRC)
Laboratory of Molecular Biology, the Wellcome Trust-MRC Institute of
Metabolic Science and the Cancer Research UK Cambridge Institute. The
AstraZeneca facility will occupy approximately 11 acres of the 70 acre campus,
which benefits from a central Cambridge location and strong infrastructure
links.

Pascal Soriot, Chief Executive Officer of AstraZeneca said: “Cambridge competes
on the global stage as a respected innovation hub for life sciences and our
choice of site puts us at the heart of this important ecosystem, providing
valuable collaboration opportunities. Moving to the Cambridge Biomedical Campus
means our people will be able to rub shoulders with some of the world’s best
scientists and clinicians carrying out some of the world’s leading research –
that’s a really exciting prospect. We hope that our move will contribute to the
growing success of Cambridge.

“Today’s announcement also confirms AstraZeneca’s long-standing commitment to
the UK and increases the chances that the next generation of medicines will be
discovered here in Britain.”

David Willetts MP, Minister for Universities and Science at the Department for
Business, Innovation and Skills, said: “AstraZeneca’s investment is excellent
news for the UK life sciences industry. It strengthens our global
competitiveness and supports our aim of making the UK the best place in the
world for the discovery and commercialisation of medical innovations. These are
key themes of the Government's life sciences strategy."

Professor Sir Leszek Borysiewicz FRS, Vice-Chancellor of the University of
Cambridge, said: “I am delighted with AstraZeneca’s choice. It is a measure of
the world-class environment that Cambridge offers to knowledge-based industries
and it reflects AstraZeneca’s commitment to making new discoveries. Over 1,500
companies in the Cambridge cluster of high-tech industries have found that
proximity – to the University, to our NHS partners, and to each other – enables
productive relationships and stimulates competition. As a global player,
AstraZeneca will add tremendously to that environment and we look forward to the
creative collaborations that will surely follow.”

– ENDS –

NOTES TO EDITORS

To obtain images of the new site, please visit our photo
library (http://www.astrazeneca.com/Media/Photo-library) or contact the media
team (details below).

About the Cambridge Biomedical Campus
Located at the heart of Europe’s leading commercial biotechnology cluster, the
Cambridge Biomedical Campus combines world-class biomedical research, patient
care and education on a single site. Now undergoing a major expansion which
includes the location of companies alongside the thriving community of academics
and healthcare professionals, the Campus is on track to becoming one of the
leading biomedical centres in the world by 2020. For more information please
visit: www.cambridge-biomedical.com

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Esra Erkal-Paler                          +44 20 7604 8030 (UK/Global)
Ayesha Bharmal                          +44 20 7604 8034 (UK/Global)
Vanessa Rhodes                        +44 20 7604 8037 (UK/Global)
Jacob Lund                                  +46 8 553 260 20 (Sweden)

Investor Enquiries
James Ward-Lilley                      +44 20 7604 8122   mob: +44 7785 432613
Karl Hård                                      +44 20 7604 8123  mob: +44 7789
654364
Colleen Proctor                           + 1 302 886 1842     mob: +1 302 357
4882
Ed Seage                                     + 1 302 886 4065     mob: +1 302
373 1361